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post-treatment with tocotrienols in a rat model of local heart 
irradiation. 
Materials and Methods: Male Sprague-Dawley rats received localized 
image-guided X-ray irradiation of the heart with a single dose of 21 
Gy. Groups of animals received a tocotrienol-enriched oral 
formulation 24 hours before irradiation, or in combination with 
pentoxifylline (PTX) starting 3 months after irradiation. At 6 months 
after irradiation, cardiac function and tissue structure were measured 
with echocardiography and histopathology. At time points from 6 
hours to 9 months after irradiation, left ventricular molecular changes 
were examined with real-time PCR and Western-Blots. In addition, 
mitochondria were isolated from left ventricular tissue samples to 
examine mitochondrial membrane potential, mitochondrial transition 
pore activity, and respiration. 
Results: Local heart irradiation caused long term changes in cardiac 
function and structure, coinciding with changes in the expression of 
mediators of the epidermal growth factor receptor (EGFR) pathway, 
and changes in mitochondrial membrane properties and respiration. 
Pretreatment of rats with tocotrienols prevented these effects of 
radiation. Unexpectedly, the late treatment with PTX caused 
bradycardia and arrhythmia in irradiated animals. This adverse event 
was not prevented when tocotrienols were added to the PTX 
treatment. On the other hand, addition of tocotrienols reduced 
cardiac numbers of macrophages and mast cells and enhanced left 
ventricular gene expression of the EGFR mediator neuregulin-1.  
Conclusions: These studies suggest that tocotrienols may be potent 
protectors against cardiac radiation toxicity. Further studies should 
address the effects of tocotrienols when administered after 
irradiation, alone or in combination with other potential mitigators.  
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Purpose/Objective: The radiation dose that can be delivered to 
thoracic tumors is limited by the risk of radiation-induced lung 
toxicity (RILT). ACE-inhibition has been shown to ameliorate RILT in 
rats although the exact mechanism is not elucidated (1). Recently, we 
found that pulmonary vascular remodeling plays an important role in 
the development of RILT in rats resulting in pulmonary hypertension, 
right ventricle hypertrophy and eventually to cardio-pulmonary 
dysfunction (2). We hypothesized that the protective effect of ACE-
inhibition might be due to reduced vascular remodeling and 
pulmonary hypertension. Therefore, in this study we investigated if 
ACE-inhibition ameliorates early radiation-induced cardio-pulmonary 
dysfunction by protection of pulmonary vascular remodeling. 
Materials and Methods: To elucidate the exact protective mechanism 
of ACE-inhibition on early radiation-induced cardio-pulmonary 
function loss rats' lungs, heart or heart and lung were irradiated to 20 
Gy using high-precision proton beams. Captopril was administered in 
the drinking water immediately after irradiation. Cardio-pulmonary 
performance was assessed in the irradiated rats (± captopril) using 
biweekly breathing rate measurements. At 8 weeks post-irradiation, 
when early radiation-induced cardio-pulmonary dysfunction peaks (2), 
left- and right-sided cardiac hemodynamics were measured, CT scans 
and histopathology were analyzed. 
Results: At 8 weeks post-irradiation breathing rate measurements 
showed that captopril significantly improved the rats' cardiac/ 
pulmonary function, but only in the rats where the heart was included 
in the radiation field. Consistently, CT scans showed improvement of 
pulmonary density/structure by captopril only in the heart-irradiated 
groups. 
This protective effect could not be explained by protection of the 
pulmonary vasculature or pulmonary artery pressure changes, which 
were equally damaged with or without captopril. Interestingly, 
besides decreasing the presence of pleural and pericardial effusion, 
left ventricle hemodynamic measurements showed better cardiac 
function parameters in the captopril treated rats. Next to that, 
captopril treatment reduced perivascular fibrosis in the irradiated 
hearts.  
Conclusions: Captopril ameliorates early radiation-induced cardio-
pulmonary dysfunction by reducing acute heart damage and 
consequentially reduces excess RILT caused by inclusion of the heart 
in the irradiation field (3). ACE-inhibition may be a promising strategy 
to reduce early cardio-pulmonary complications induced by 
radiotherapy to the thoracic area in patients receiving a dose to the 
heart.  
 (1) Ghosh et al. Int J Radiat Oncol Biol Phys 2009 
(2) Ghobadi et al. Thorax 2011 
(3) van Luijk et al. Cancer Res 2005 
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Purpose/Objective: This study describes a new treatment verification 
system, based on electronic portal imaging device (EPID) images, for 
HDR brachytherapy. The phantom study incorporates verification of 
both source position and dose as the brachytherapy treatment plan is 
delivered, identifying the potential for real time identification of 
incorrect dose to patients. 
Materials and Methods: An a-Si EPID (IAS11-19, Varian Medical 
Systems,Palo Alto, CA, USA) was used for all measurements. Response 
characteristics of the EPID were determined for use with an Ir-192 
HDR brachytherapy source, including linearity, reproducibility, 
variation in exposure time, image acquisition time,photon energy 
dependence and source position determination in three dimensions.A 
treatment plan was delivered to the phantom and for each dwell 
position in the delivered plan, planar EPID dose distributions were 
compared with the TPS calculated at the same plane. 
Results: Analysis of the EPID images containing the source response 
distribution, yielded the location of the source to better than ± 1mm 
for coordinates parallel to the plane of the EPID at source-to-detector 
distances up to 200mm. The source distance from the EPID surface 
could be determined to within ± 1.5 mm. The comparison of TPS and 
measured dose at a plane 100mm from the brachytherapy source 
agreed to within ± 2% for a 100 x 100 mm region of the EPID plane 
centered at the source (x,y)coordinates, and agreed to within ± 7% 
across the entire EPID panel (300x400mm). Delivery of an erroneous 
treatment plan with missing or incorrectly located dwell positions was 
easily identifiable with this system. 
Conclusions: This is the first system, to our knowledge, providing a 
check of both source position and dwell time during dose delivery. 
The EPID images are sensitive enough to reveal clinically relevant 
source position and dwell time errors. We have established a proof-of-
principle that an EPID can be used for treatment verification in HDR 
brachytherapy.  
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Purpose/Objective: To correlate the dose-volume parameters D90 (Gy) 
and V100 (%) (i.e. minimum dose to 90% of the prostate volume and 
volume that received 100% of the prescribed iso-dose, respectively) 
with biochemical control in patients with advanced prostate cancer 
treated with external beam radiotherapy (EBRT) followed by a boost 
of high-dose rate brachytherapy (HDR-BT). 
Materials and Methods: 108 patients, participating in a randomised 
trial of EBRT± HDR-BT, received EBRT to 35.75 Gy in 13 fractions 
followed by HDR-BT of 2 x 8.5 Gy. Kaplan-Meier freedom-from-
biochemical relapse (FFbR) rates were obtained by stratifying the data 
by those whose D90 and V100 were at or above and below the first (Q1), 
second (Q2) and third (Q3) quartile. Differences between groups were 
compared using the log-rank test. Univariate and multivariate hazard 
ratios for D90 and V100 and other co-variates (prostate specific antigen 
(PSA), androgen deprivation therapy (ADT)) were obtained using Cox's 
proportional hazard model. 
